Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01609556 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors
A Phase 1 study, sponsored by ImmunoGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 206
- Enrollment target
NCT01609556 is a Phase 1 study that has completed, run by ImmunoGen. The registered enrollment target is 206 participants.
The verdict
NCT01609556, a Phase 1 study, has completed, sponsored by ImmunoGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 206 participants
- Enrollment target
Study Summary
The purpose of this study is to test mirvetuximab soravtansine (IMGN853) in participants with ovarian cancer and other FOLR-1 positive tumors.
Interventions
- DRUG Mirvetuximab soravtansine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2012-06-28 |
| Est. Completion | 2018-03-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01609556
The ClinicalTrials.gov registry entry for NCT01609556 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoGen, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mirvetuximab soravtansine is the first listed.
NCT01609556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01609556 about?
NCT01609556 is a clinical study titled "First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors". The purpose of this study is to test mirvetuximab soravtansine (IMGN853) in participants with ovarian cancer and other FOLR-1 positive tumors.
What is the current status of trial NCT01609556?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 206 participants. The study started on 2012-06-28. Estimated completion is 2018-03-19.
What interventions are being tested in trial NCT01609556?
The interventions under investigation include: Mirvetuximab soravtansine (DRUG).
Who is sponsoring clinical trial NCT01609556?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.